The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. The metric has seen a significant loss of -19.32% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 5.45%. Over the past 30 days, the price of CUE has fallen by 19.66%. And in the last five days, it has surged by 56.04%.
Cue Biopharma Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $5.12 on 05/10/23, with the lowest value being $1.30 on 04/25/24.
52-week price history of CUE Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Cue Biopharma Inc’s current trading price is -58.40% away from its 52-week high, while its distance from the 52-week low is 63.51%. The stock’s price range over this timeframe has been between $1.30 and $5.12. The shares of the Healthcare sector company recorded a trading volume of approximately 0.66 million for the day, which was comparatively higher than the average daily volume of 0.28 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Cue Biopharma Inc (CUE) has experienced a quarterly decline of -13.06% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 103.60M and boasts a workforce of 53 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.26, with a change in price of -0.96. Similarly, Cue Biopharma Inc recorded 309,005 in trading volume during the last 100 days, posting a change of -31.07%.
CUE’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CUE stands at 0.40. Similarly, the long-term debt-to-equity ratio is also 0.20.
CUE Stock Stochastic Average
Cue Biopharma Inc’s raw stochastic average for the past 50 days is currently at 77.51%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 93.24%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 81.66% and 71.45%, respectively.
